180 related articles for article (PubMed ID: 11366488)
1. Abacavir update.
Proj Inf Perspect; 1998 Dec; (26):11. PubMed ID: 11366488
[TBL] [Abstract][Full Text] [Related]
2. Ziagen (abacavir) approved: caution essential.
James JS
AIDS Treat News; 1999 Jan; (No 310):1, 3-6. PubMed ID: 11366148
[TBL] [Abstract][Full Text] [Related]
3. Abacavir sulfate (Ziagen).
Simmons P
Res Initiat Treat Action; 1999 Apr; 5(2):8-10. PubMed ID: 11366289
[TBL] [Abstract][Full Text] [Related]
4. Abacavir gets green light from FDA advisory board. Food and Drug Administration.
TreatmentUpdate; 1998 Nov; 10(9):3-4. PubMed ID: 11365924
[TBL] [Abstract][Full Text] [Related]
5. FDA approves abacavir. Food and Drug Administration.
Highleyman L
BETA; 1999 Jan; 12(1):3. PubMed ID: 11367235
[TBL] [Abstract][Full Text] [Related]
6. Abacavir (Ziagen) approval recommended.
AIDS Treat News; 1998 Nov; (No 306):4. PubMed ID: 11365961
[TBL] [Abstract][Full Text] [Related]
7. Abacavir's trials and tribulations.
Gilden D
GMHC Treat Issues; 1998 Nov; 12(11):1-3. PubMed ID: 11365905
[TBL] [Abstract][Full Text] [Related]
8. Abacavir at last.
Gilden D
GMHC Treat Issues; 1998 Mar; 12(3):9. PubMed ID: 11365394
[TBL] [Abstract][Full Text] [Related]
9. Glaxo opens broad expanded access program for abacavir (Ziagen).
Baker R
BETA; 1998 Apr; ():6. PubMed ID: 11365271
[TBL] [Abstract][Full Text] [Related]
10. New abacavir data open door to a better treatment paradigm.
AIDS Alert; 1998 Aug; 13(8):85-7. PubMed ID: 11365647
[TBL] [Abstract][Full Text] [Related]
11. Abacavir for salvage or intensification.
Torres G
GMHC Treat Issues; 1999 Jan; 13(1):4-5. PubMed ID: 11366111
[TBL] [Abstract][Full Text] [Related]
12. Generic lamivudine and abacavir approved.
AIDS Patient Care STDS; 2008 Nov; 22(11):918. PubMed ID: 19043839
[No Abstract] [Full Text] [Related]
13. 1592 (abacavir, or new name Ziagen) more widely available March 23.
AIDS Treat News; 1998 Mar; (No 291):6-7. PubMed ID: 11365246
[TBL] [Abstract][Full Text] [Related]
14. Glaxo Wellcome's two new drugs.
Res Initiat Treat Action; 1998 Dec; 4(7):14. PubMed ID: 11366081
[TBL] [Abstract][Full Text] [Related]
15. Once-daily abacavir in place of twice-daily administration.
Goedken AM; Herman RA
Ann Pharmacother; 2005; 39(7-8):1302-8. PubMed ID: 15956231
[TBL] [Abstract][Full Text] [Related]
16. Next HIV guidelines likely to include salvage therapy.
AIDS Alert; 1999 Jul; 14(7):76-8. PubMed ID: 11366417
[TBL] [Abstract][Full Text] [Related]
17. Treatment intensification with abacavir in HIV-infected patients with at least 12 weeks previous lamivudine/zidovudine treatment.
Rozenbaum W; Katlama C; Massip P; Bentata M; Zucman D; Delfraissy JF; Trepo C; David F; Lanier ER; Vavro C; Mamet JP
Antivir Ther; 2001 Jun; 6(2):135-42. PubMed ID: 11491418
[TBL] [Abstract][Full Text] [Related]
18. Intracellular cytokines may model immunoregulation of abacavir hypersensitivity in HIV-infected subjects.
King D; Tomkins S; Waters A; Easterbrook PJ; Thurmond LM; Thorborn DE; Raffi F; Kemeny DM; Vyakarnam A
J Allergy Clin Immunol; 2005 May; 115(5):1081-7. PubMed ID: 15867870
[TBL] [Abstract][Full Text] [Related]
19. Abacavir expanded access program for adult patients infected with human immunodeficiency virus type 1.
Kessler HA; Johnson J; Follansbee S; Sension MG; Mildvan D; Sepulveda GE; Bellos NC; Hetherington SV
Clin Infect Dis; 2002 Feb; 34(4):535-42. PubMed ID: 11797183
[TBL] [Abstract][Full Text] [Related]
20. Incidence of abacavir hypersensitivity reactions in euroSIDA.
Bannister WP; Friis-Møller N; Mocroft A; Viard JP; van Lunzen J; Kirk O; Gargalianos P; Bánhegyi D; Chiesi A; Lundgren JD;
Antivir Ther; 2008; 13(5):687-96. PubMed ID: 18771052
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
